跳至主要内容
临床试验/NL-OMON47132
NL-OMON47132已完成不适用

A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in males <= 17 years of age undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy. - ALD-103

bluebird bio0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
bluebird bio
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
2 至 17(—)

入选标准

  • Subjects must:
  • 1. Provide informed consent from a competent custodial parents or guardian with legal capacity to execute a local Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent. In addition, informed assent will be sought from capable subjects, in accordance with the directive of the IRB/IEC and with local requirements.
  • 2. Be male and <=17 years of age at the time of treatment, for retrospective and partial prospective/retrospective subjects, or at time of parental/guardian consent and, where appropriate, subject assent.
  • 3. Have a confirmed diagnosis of CALD as defined by abnormal VLCFA profile and cerebral lesion on brain MRI.
  • 4. Depending on the cohort, the subject must:
  • - Be scheduled for allo-HSCT evaluation/procedure at a study site (prospective cohort only)
  • - Received an allo-HSC infusion and to be consented in time to complete the Month 24 Visit on study (partial prospective/retrospective cohort only) or
  • - Have received their most recent allo-HSC infusion on or after January 1, 2013 (retrospective cohort only).

排除标准

  • Subjects are excluded if they meet any of the following criteria.
  • 1. Previous treatment with a gene therapy product.
  • 2. Receipt of an experimental transplant procedure.

研究者

发起方
bluebird bio

相似试验

A Prospective and Retrospective Data Collection... | 临床试验